Kevin Mann avoids dutasteride because it comes in gelatin capsules, which he avoids as a vegan, and he is satisfied with finasteride's results. He prefers finasteride due to more long-term research and follows the principle of "if it ain't broke, don't fix it."
A 28-year-old has been using oral dutasteride 0.5 mg, topical minoxidil 5%, and Cafune shampoo for 104 days with positive results and is considering adding microneedling. No side effects from dutasteride have been reported.
Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.
A user experienced a "watery belly" and cellulite after starting finasteride, despite maintaining a disciplined fitness routine. Others suggest checking hormone levels, as changes in DHT and estrogen could affect fat metabolism, but age might also be a factor.
The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.
Musely sells a hair topical solution containing latanoprost, which degrades in 6 weeks, yet they market it as a 3-month supply. Concerns are raised about the product's effectiveness and the company's sales strategy.
The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.
A user is seeking a European supplier for a 3-in-1 hair loss medication containing Minoxidil, Finasteride, and Biotin. Suggestions include using forwarding services and a UK-based provider, with discussions on potential import taxes.
The user shared their one-year hair growth progress using a daily Fin/Min chewable tablet, noting some inconsistency in usage but still achieving results. They use Head & Shoulders shampoo and have not mentioned any side effects.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
A user started finasteride and is experiencing fatigue and nipple tenderness. They are considering DIM supplements to manage elevated estrogen levels, and another user suggests these side effects may resolve in a month.
A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.
Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.
Apple core extract pills, believed to enhance hair density, are discussed as a potential treatment for hair loss. Users express cautious optimism and interest in trying the product, while acknowledging skepticism and the high cost.
A healthy scalp barrier is crucial for hair growth, and ceramides may play a key role in maintaining it. The conversation suggests that focusing on scalp health, alongside treatments like Minoxidil, Finasteride, and RU58841, could improve hair follicle health.
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
DIM is suggested to help with estrogen metabolism for those on finasteride or dutasteride, potentially reversing side effects like fat gain and mood changes. Some users doubt its effectiveness, recommending lifestyle changes or consulting a doctor instead.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
A person with alopecia universalis is considering using Xeljanz but is advised that Olumiant is more effective for their condition. They are under a dermatologist's care and should expect gradual progress, as follicles dormant for 20 years are challenging to reactivate.
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.
A user shared their hair regrowth progress using a regimen of finasteride, minoxidil, derma stamping, red light therapy, and supplements like biotin and vitamin D. They also use keto shampoo and Alpecin C1 shampoo, exercise regularly, and follow a keto diet.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.